The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Exploratory analysis of angiotensin converting enzyme (ACE) and aldosterone (Ald) serum levels as prognostic and predictive biomarkers on the NCIC CTG BR24 trial.
Jair Bar
Consultant or Advisory Role - AstraZeneca
Keyue Ding
No relevant relationships to disclose
Huijun Zhao
No relevant relationships to disclose
Scott Andrew Laurie
Research Funding - AstraZeneca
Lei Han
No relevant relationships to disclose
Frances A. Shepherd
Consultant or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck; Recombio; Roche
Stock Ownership - Lilly; Pfizer
Honoraria - GlaxoSmithKline; Lilly; Roche
Expert Testimony - AstraZeneca
Christina L. Addison
No relevant relationships to disclose
Glenwood D. Goss
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Jim Dimitroulakos
No relevant relationships to disclose
Penelope Ann Bradbury
Research Funding - AstraZeneca